Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir.
about
Targeting Innate Immunity for Antiviral Therapy through Small Molecule Agonists of the RLR PathwayNatural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naïve HIV/HCV Co-Infected Patients in ChinaCost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy.Serum Inter-Alpha-Trypsin Inhibitor Heavy Chain 4 (ITIH4) in Children with Chronic Hepatitis C: Relation to Liver Fibrosis and Viremia.Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C.Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antiviral drugsHCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection.Advances in and the future of treatments for hepatitis C.Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir.Predominance of hepatitis C virus Q80K among NS3 baseline-resistance-associated amino acid variants in direct-antiviral-agent-naïve patients with chronic hepatitis: single-centre experience.Safety and efficacy of faldaprevir in combination with pegylated interferon α-2b and ribavirin in Japanese patients with genotype-1 chronic hepatitis C virus infection.Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies.No correspondence between resistance mutations in the HCV-NS3 protease at baseline and early telaprevir-based triple therapy.In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir.Comparison of first- and second-wave DAAs for HCV GT1: efficacy, safety, tolerability, and regimen complexity.
P2860
Q26700090-CD7C2092-9C58-426E-989B-E3C6F6323646Q28552134-5F160E02-0589-43DD-B529-A89BBA02CF92Q33831652-9EA7A11C-9F5F-43F9-902C-190FFDE5269CQ34008754-A6802F4A-CE87-4048-BDFB-608AC577AABBQ34256849-F5B9E441-2815-403E-BCB0-E5137B386DF6Q35061753-BF520970-130B-403E-8F3A-448E50F143CAQ36290416-3FFD647E-6F05-4975-9C13-1EE09604977DQ37446584-6EE8C8A0-5378-4990-A9B7-3381596FD040Q38213321-F9C96EEB-FDA5-4AD7-B9F1-29C837D922B1Q40587241-434EE83E-C210-4CC5-9EA1-D2F03D68A21FQ40651570-081724DE-022A-4E53-AB56-E23B33419273Q40684633-BCC167A6-1E29-4570-B452-8C5530801D2BQ40714351-1552B289-E40D-41AC-A3D7-874B1572A2C1Q40868771-E2C85A3A-A817-4704-BDA5-2E2E7D2FB128Q45325504-D4F0CB82-EF26-4BE7-A4D6-6A5A273B6C08Q46661989-0B27B547-C2F7-43AC-821D-59DDC350A20D
P2860
Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Baseline hepatitis C virus (HC ...... rotease inhibitor faldaprevir.
@en
type
label
Baseline hepatitis C virus (HC ...... rotease inhibitor faldaprevir.
@en
prefLabel
Baseline hepatitis C virus (HC ...... rotease inhibitor faldaprevir.
@en
P2093
P2860
P356
P1476
Baseline hepatitis C virus (HC ...... rotease inhibitor faldaprevir.
@en
P2093
George Kukolj
Gerhard Steinmann
Ibtissem Triki
Jerry O Stern
Joseph Scherer
Kristi L Berger
Marie-Josée Massariol
Martin Marquis
Mireille Cartier
Wulf O Böcher
P2860
P304
P356
10.1128/AAC.01976-13
P407
P577
2013-11-11T00:00:00Z